免疫原
The antiserum was produced against synthesized peptide derived from human RECK. AA range:21-70
特异性
RECK Polyclonal Antibody detects endogenous levels of RECK protein.
来源
Polyclonal, Rabbit,IgG
组成(Formulation)
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
稀释比例
WB 1:500-2000 Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications.
纯化工艺(Immunogen)
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
背景(Background)
The protein encoded by this gene is a cysteine-rich, extracellular protein with protease inhibitor-like domains whose expression is suppressed strongly in many tumors and cells transformed by various kinds of oncogenes. In normal cells, this membrane-anchored glycoprotein may serve as a negative regulator for matrix metalloproteinase-9, a key enzyme involved in tumor invasion and metastasis. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015],
功能
function:Negatively regulates matrix metalloproteinase-9 (MMP-9) by suppressing MMP-9 secretion and by direct inhibition of its enzymatic activity. RECK down-regulation by oncogenic signals may facilitate tumor invasion and metastasis. Appears to also regulate MMP-2 and MT1-MMP, which are involved in cancer progression.,PTM:N-glycosylated.,similarity:Contains 3 Kazal-like domains.,subunit:Interacts with MMP-9.,tissue specificity:Expressed in various tissues and untransformed cells. It is undetectable in tumor-derived cell lines and oncogenically transformed cells.,
蛋白名称
Reversion-inducing cysteine-rich protein with Kazal motifs
其他名称
RECK; ST15; Reversion-inducing cysteine-rich protein with Kazal motifs; hRECK; Suppressor of tumorigenicity 15 protein
Fields
>>MicroRNAs in cancer
细胞定位
Cell membrane ; Lipid-anchor, GPI-anchor .
组织表达
Expressed in various tissues and untransformed cells (PubMed:9789069). It is undetectable in tumor-derived cell lines and oncogenically transformed cells (PubMed:9789069).